These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 23666608)
1. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608 [TBL] [Abstract][Full Text] [Related]
2. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931 [TBL] [Abstract][Full Text] [Related]
3. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. Husni ME; Kavanaugh A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Harrison DD; Han C Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771 [TBL] [Abstract][Full Text] [Related]
4. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702 [TBL] [Abstract][Full Text] [Related]
5. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). Kavanaugh A; Mease P J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603 [TBL] [Abstract][Full Text] [Related]
6. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C; J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912 [TBL] [Abstract][Full Text] [Related]
7. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Kavanaugh A; Antoni C; Krueger GG; Yan S; Bala M; Dooley LT; Beutler A; Guzzo C; Gladman D Ann Rheum Dis; 2006 Apr; 65(4):471-7. PubMed ID: 16096330 [TBL] [Abstract][Full Text] [Related]
8. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Ogdie A; Walsh JA; Chakravarty SD; Peterson S; Lo KH; Kim L; Li N; Hsia EC; Chan EKH; Kavanaugh A; Husni ME Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380 [TBL] [Abstract][Full Text] [Related]
9. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial. Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770 [TBL] [Abstract][Full Text] [Related]
10. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964 [TBL] [Abstract][Full Text] [Related]
11. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944 [TBL] [Abstract][Full Text] [Related]
12. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C; Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458 [TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045 [TBL] [Abstract][Full Text] [Related]
14. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455 [TBL] [Abstract][Full Text] [Related]
15. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Rahman P; McInnes IB; Deodhar A; Schett G; Mease PJ; Shawi M; Cua DJ; Sherlock JP; Kollmeier AP; Xu XL; Sheng S; Ritchlin CT; McGonagle D Clin Rheumatol; 2024 May; 43(5):1591-1604. PubMed ID: 38472528 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685 [TBL] [Abstract][Full Text] [Related]
17. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Kavanaugh A; van der Heijde D; Beutler A; Gladman D; Mease P; Krueger GG; McInnes IB; Helliwell P; Coates LC; Xu S Arthritis Care Res (Hoboken); 2016 Feb; 68(2):267-74. PubMed ID: 25779603 [TBL] [Abstract][Full Text] [Related]
18. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868 [TBL] [Abstract][Full Text] [Related]
19. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]